First skincare line featuring patented purified amniotic stem cell technology, sparking new momentum in the premium medical-grade skincare market
Chlitina Holding Limited (hereinafter “Chlitina-KY,” Stock Code: 4137) announced the Global Launch Conference of the Chlitina Golden Remedy in Wuhan, China, on May 9. At the event, Chlitina unveiled its major innovation of the year, the “Skin Radiance Refining Essence Series,” achieving on-site sales of over RMB 10 million in a single day, and underscoring Chlitina’s leading position in the premium skincare market.
Euromonitor International also issued a statement confirming that Chlitina is the first Chinese beauty brand worldwide to launch skincare products featuring Deer Amniotic Fluid Extract (D-AFE®). This marks the first appearance of such an ingredient in China’s skincare market and signals Chlitina’s strategic commitment to the premium skincare segment. The event generated intense enthusiasm, with franchisees rushing to place orders, strong consumer demand, and extensive media coverage — showcasing the combined power of Chlitina’s products, brand, and distribution channels.
According to Chlitina-KY, the Skin Radiance Refining Essence Series represents Chlitina’s latest medical-grade skincare portfolio. As the world’s first skincare line centered on deer amniotic fluid extract, it integrates regenerative medicine and stem cell technology with active ingredients such as PDRN (derived from salmon DNA) and adenosine, formulated in a golden ratio. This breakthrough moves beyond traditional anti-aging products that focus only on surface repair, opening a new chapter in deep anti-aging. The series creates a perceptible “activate–repair–regenerate” cycle, stimulating the skin’s natural repair mechanisms, enhancing regeneration, and restructuring skin quality for visible rejuvenation. With patented encapsulation technology, absorption and stability are significantly improved, providing both immediate soothing and long-term dermal strengthening.
Inspired by the concept of “gold remedy,” the product’s packaging symbolizes the promise to “lock in youth,” offering deep care akin to post-procedure repair in aesthetic medicine. This unique design won the 2024 French Design Gold Award, demonstrating Chlitina’s spirit of transforming medical aesthetics into artistry and setting a new benchmark in premium skincare aesthetics.
Chlitina-KY further emphasized that the Skin Radiance Refining Essence Series is a key strategic initiative in medical-grade skincare. Leveraging cutting-edge scientific R&D and aligned with market trends, the series continues the brand’s strategy of “Precision Skincare, Smart Anti-Aging,” with a core focus on skin repair and rejuvenation. Targeting affluent, mature consumers with strong demand for post-procedure care and needle-free anti-aging solutions, the series supports Chlitina’s “Awakening Beauty” strategy. As Chlitina-KY pursues brand upgrading and market transformation, it will continue to strengthen its core competitiveness of scientific beauty, commercializing R&D outcomes and embedding esthetic standards into brand identity — leading the premium skincare market from emotional appeal toward rational, science-driven innovation.
The successful launch of the Skin Radiance Refining Essence Series and its strong sales performance fully demonstrate Chlitina’s integrated strengths in products, branding, and distribution. With nearly 40 years of industry experience, Chlitina continues to allocate a fixed portion of annual investment to R&D, including developing patented cosmetic ingredients, unique formulations, and specialized projects. Tailoring offerings to different channels and consumer groups, Chlitina consistently delivers professional, high-quality, and premium skincare products.
Looking ahead, Chlitina Group CEO Mr. Ryan Chao stated: “Chlitina does not predict the future — Chlitina creates the future.” The company will continue to strengthen R&D capabilities and apply digital marketing tools, advancing its integrated Brand × Technology × Channel strategy. This will accelerate the adoption of premium beauty solutions in key consumption scenarios through AI-driven skin diagnostics, personalized product recommendations, and intelligent skincare tutorials — creating a smart beauty ecosystem shared by consumers and franchise stores. With this, Chlitina is committed to realizing its vision of “Technology Driving the Future of Beauty,” consolidating its competitive advantage in Asia’s premium skincare market.
As medical-grade skincare trends and next-generation consumer demands evolve, Chlitina will further advance the integration of technology and beauty. Through continuous product innovation and deeper service engagement, the Company will expand premium skincare solutions across Asia, elevating the Group’s operations to new heights.
Press Contact:
IR Trust Deputy General Manager Vicky Chang
(02)2585-5701/0920-286-136 vicky@ir-trust.tw
Investor Relations Contact:
Chlitina Holding Limited Chief Financial Officer Eric Yeh
(02)2723-8666 ir@chlitinaholding.com
